Pharmaceutical Stocks
Recent market-moving SEC filings and news across pharmaceutical companies, ranked by Wiseek's 1–10 importance score.
How Wiseek curates this list
Every item here is a high-importance (score ≥ 7) SEC filing or licensed news event for a pharmaceutical company, sourced from SEC EDGAR and licensed news wires and ranked by Wiseek's 1–10 importance score. The underlying source is linked from each article. See our methodology and editorial policy.
Related Healthcare industries
Biotech StocksMedical Device StocksHealth Tech StocksDiagnostics & Research StocksMedical Instrument StocksHealthcare Facility Stocks
See the full Healthcare sector feed.
Evolus Partners with IBSA for Exclusive U.S. Rights to Market-Leading Profhilo® Skin Quality Injectable
DeepSolar AI Platform Validated, Nearing Commercial Launch for Renewable Energy Optimization
Shareholders Approve Esperion Therapeutics Acquisition by Essence Parent
DeepSolar AI Platform Validated for Renewable Energy Optimization, Nearing Commercial Launch
Alkermes Terminates Authorized Generic Agreement for VIVITROL®
FDA Warning Letter Hits Amphastar Subsidiary for Manufacturing Compliance
Major Shareholder Disposes of 500,000 Scilex Shares to Fund Acquisition
FDA Issues Warning Letter to Amphastar Subsidiary Over Manufacturing Violations
Opaleye Management Sells $4.77M in Eton Pharmaceuticals Stock
Registers Resale of 157.5M Shares from Highly Dilutive $30M Pre-Paid Purchase Financing
Pfizer Stock Down 33% Over Decade, Earnings Expected to Decline Through 2029
Sanofi's Nexviazyme Achieves Positive Phase 3 Results for Infantile-Onset Pompe Disease
Perrigo Finalizes Interim CEO Compensation with $2.5M RSU Grant
Secures up to $30M in Highly Dilutive 'Pre-Paid Purchase' Financing
AbbVie Lowers Full-Year EPS Guidance by $0.17 Due to Q2 IPR&D Expenses
FDA Accepts ReNu BLA for Knee OA; Organogenesis Sets April 2027 PDUFA Date
AbbVie's TEPKINLY Approved in Europe for Follicular Lymphoma, Offering Chemotherapy-Free Option
SKNY-1 Shows Favorable Oral Bioavailability, Brain Penetration in Preclinical Study
MIRA Pharmaceuticals Reports Positive Preclinical Data for Optimized Oral SKNY-1 Formulation
Prestige Consumer Healthcare Finalizes LaCorium Acquisition, Prices $400M Senior Notes at 6.25%
Prestige Consumer Healthcare Finalizes LaCorium Acquisition, Prices $400M Senior Notes
Merck Halts Mid-Stage Alzheimer's Drug Trial MK-1167 for Business Reasons
AbbVie's Epcoritamab Achieves Phase 3 Win in DLBCL Trial
Amgen's Tavneos Trial Retracted Over FDA-Found Altered Data; Company Sues Colorado Over Enbrel Price Cap
Scilex Secures Binding Term Sheet for $100M Investment at 65% Premium
Gelteq Secures $2.5M in Critical Convertible Debt Financing After Shareholder Approval
Former Major Shareholder Sells $306K in KALA BIO Stock, Reduces Stake Below 5%
Activist Legion Partners Demands Full Cash Redemption of $12.5M Preferred Stock by Year-End
Lifecore Biomedical Faces $52.1M Preferred Stock Redemption, Requires Lender Consent Amid Liquidity Shortfall
Activist Investor 22NW Demands Full Preferred Stock Redemption, Threatens Litigation
Radnostix Acquires Lucerno Dynamics Assets, Expanding Radiopharma Portfolio
RedHill Biopharma Registers 26.2M ADSs for Resale, Potential $13.8M from Warrant Exercises
NMPA Approves ORPATHYS® for MET-Amplified Gastric Cancer in China
10% Owner HRT Financial LP Buys $110K in Shuttle Pharmaceuticals Stock
IM Cannabis Secures Another Highly Dilutive Convertible Note and Warrants for $225K
Judge Blocks Colorado's Enbrel Price Cap, Protecting Amgen's Blockbuster Drug Revenue
China SXT Pharmaceuticals Reports Steep Revenue Decline, Surging Losses, and Critical Internal Control Failures
¥40 Billion Term Loan Refinanced by Viatris, Extending Maturity to 2029
Viatris Refinances ¥40 Billion Term Loan, Extending Maturity to 2029
Cumberland Pharmaceuticals Closes $100M Asset Sale to Apotex, Pivots to Rare Disease Pipeline